Global News and Digital Insights
for the Healthcare Industry

Glenmark Pharma’s Ryaltris nasal spray for allergic rhinitis to be launched in the US market

Glenmark Pharmaceutical has launched its therapy for seasonal allergic rhinitis in the US. The nasal spray is the only-approved and fixed-dose combination treatment for seasonal rhinitis. With the help of Hikma Pharmaceuticals, a British drug giant, the Ryaltris nasal spray will be channelled in the US market. Unless Ryaltris is covered under insurance plans, according to the co-pay mechanism, patients will have to pay $49, said Glenmark’s CEO of Global Formulations Business.

Read More from Business Standard